中国临床药理学杂志2018，Vol.34Issue(10)：1257-1260,4.DOI:10.13699/j.cnki.1001-6821.2018.10.034
以淀粉样蛋白为靶点的抗阿尔茨海默病药物研发进展
Review on the development of anti-alzheimer's drugs targeting amyloid peptide
摘要
Abstract
Alzheimer' s disease (AD) is a neurodegenerative disease characterized by cognitive deficit,behavioral disturbance and decline of daily life activity.It is the 4th cause of death in the elderly.The typical pathological features of AD are deposition of neuronal extracellular amyloid (Aβ),appearance of neuronal neurofibrillary tangles (NFT)and neuronal loss.Although the pathogenesis of AD is still unclear,many animal studies have suggested that Aβ deposition is the most important factor in AD.Thus Aβ peptide is regarded as a promising target for the development of novel anti-AD drugs.This paper reviews the mechanism of action and clinical development of monoclonal antibodies and small molecule drugs targeting Aβ peptide and provides a basis for further development of anti-AD drugs.关键词
阿尔茨海默病/淀粉样蛋白/主动免疫/被动免疫/单克隆抗体/脑脊液Key words
Alzheimer's disease/amyloid peptide/active immunization/passive immunization/monoclonal antibody/cerebrospinal fluid分类
医药卫生引用本文复制引用
孙卓,陈霞..以淀粉样蛋白为靶点的抗阿尔茨海默病药物研发进展[J].中国临床药理学杂志,2018,34(10):1257-1260,4.基金项目
国家自然科学基金面上基金资助项目(81673169) （81673169）
院内重点科研基金资助项目(pumch-2016-1.8) （pumch-2016-1.8）
国家“十三五”重大新药创制专项基金资助项目 (2017ZX09304018,2018ZX09734006-001) （2017ZX09304018,2018ZX09734006-001）
